SCHEMBL5535953

SCHEMBL5535953

Cc1ccc(-n2c[c]cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.38
F2 P00734 1/20 0.38
CTSG P08311 1/20 0.38
CMA1 P23946 1/20 0.38
CTRC Q99895 1/20 0.38
TDP1 Q9NUW8 3/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
KDM4E B2RXH2 2/20 0.36
NOTUM Q6P988 1/20 0.36
ACHE P22303 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
MGLL Q99685 1/20 0.35
ADRB1 P08588 1/20 0.33
ALDH1A1 P00352 4/20 0.33
POLB P06746 3/20 0.33
LMNA P02545 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2750561 0.79 ALDH1A1 (0.41) TDP1KDM4ENOTUMALOX15TSHR
SCHEMBL2750548 0.75 HSD17B10 (0.43) TDP1KDM4ETSHRALDH1A1LMNA
SCHEMBL27517242 0.74 MAPT (0.41) NOTUMALOX15TSHRLMNAMEN1
SCHEMBL2753667 0.71 GAA (0.43) L3MBTL1ACHETSHRPOLBLMNA
SCHEMBL2752301 0.71 ALDH1A1 (0.42) ACHEADRB1ALDH1A1CYP2A6SMN1; SMN2
SCHEMBL2752355 0.71 NOTUM (0.41) L3MBTL1NOTUMADRB1ALDH1A1LMNA
SCHEMBL1366622 0.70 L3MBTL1 (0.56) ELANEF2CTSGCMA1CTRC
SCHEMBL2753389 0.67 ALDH1A1 (0.41) TDP1KDM4EALOX15TSHRADRB1
SCHEMBL18850042 0.67 MGLL (0.43) ELANEF2CTSGCMA1CTRC
SCHEMBL2753214 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-5207816-A Herbicides BASF AKTIENGESELLSCHAFT (DE) 1993-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ELANE 3771/4885F2 4718/4885CTSG 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.